BioVie Inc is a clinical-stage company developing drug therapies for the treatment of neurological and neurodegenerative disorders and liver disease. Its therapeutic areas include Alzheimer's, Parkinson's, Long COVID, Ascites, Longevity, and Epigenetics. In liver disease, its investigational drug candidate BIV201 (continuous infusion terlipressin) was granted FDA Fast Track status and FDA Orphan Drug designation for ascites due to all etiologies except cancer. BIV201 is being evaluated as a treatment option for patients suffering from life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.
Last trade$0.9756
Day change-$0.1044 (-9.67%)
Day range$0.974 – $1.14
Volume383,315
Market cap$12M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$11.58M
Price / earnings
—
Price / book
1.77×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.17×
Profitability
Earnings per share
-$2.11
Return on assets
-204.66%
Return on equity
-346.02%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
2.4×
Quick ratio
2.4×
Cash ratio
1.78×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$18.91M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for BIVI, quarterly periods
Line item
Q1 FY2027 Sep 30, 2026
Q4 FY2026 Jun 30, 2026
Q3 FY2026 Mar 31, 2026
Q2 FY2026 Dec 31, 2025
Q1 FY2026 Sep 30, 2025
Q4 FY2025 Jun 30, 2025
Q3 FY2025 Mar 31, 2025
Q2 FY2025 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$2.31M
$2.13M
$2.15M
$1.94M
$2.29M
$2.38M
$1.59M
$2.53M
Research and development
$3.34M
$3.58M
$3.18M
$4.27M
$2.94M
$1.22M
$1.34M
$4.7M
Total operating expenses
$5.65M
$5.72M
$5.39M
$6.26M
$5.28M
$3.66M
$2.99M
$7.29M
Operating income
-$5.65M
-$5.72M
-$5.39M
-$6.26M
-$5.28M
-$3.66M
-$2.99M
-$7.29M
Interest expense
-$968
-$3.98K
-$5.97K
-$5.97K
-$1.99K
-$5K
-$5K
-$66.7K
Income before taxes
-$5.61M
-$5.65M
-$5.27M
-$6.07M
-$5.09M
-$3.49M
-$2.79M
-$7.11M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$5.61M
-$5.65M
-$5.27M
-$6.07M
-$5.09M
-$3.49M
-$2.79M
-$7.11M
Net income attributable to common shareholders
-$5.61M
-$5.65M
-$5.27M
-$6.07M
-$5.13M
-$3.49M
-$2.79M
-$7.16M
EBITDA
-$5.65M
-$5.71M
-$5.33M
-$6.2M
-$5.23M
-$3.61M
-$2.93M
-$7.24M
Basic earnings per share
-$0.68
-$0.68
-$0.70
-$0.77
-$0.98
-$1.89
-$1.51
-$4.55
Diluted earnings per share
-$0.68
-$0.68
-$0.70
-$0.77
-$0.98
-$1.89
-$1.51
-$4.55
Recent news
Company coverage with links to the original publishers.
BioVie Inc. will host an investor webinar on December 9, 2025, featuring CEO Cuong Do discussing their drug candidates bezisterim and BIV201 for neurological diseases and liver cirrhosis, highlighting clinical progress and potential market opportunities.
BioVie Inc. will host an investor webinar discussing its drug therapies for neurological diseases, focusing on bezisterim for Alzheimer's, Parkinson's, and long COVID, and BIV201 for liver cirrhosis complications.
BioVie Inc. has priced a public offering of 6 million units at $2.00 per unit, expecting to raise approximately $12 million. The offering includes common stock and warrants, with proceeds intended for working capital and general corporate purposes.
BioVie Inc. is pricing a public offering of 6 million units, each consisting of one common stock share and one warrant, expected to raise approximately $12 million for working capital and general corporate purposes.
BioVie presented research showing its drug Bezisterim potentially reduces biological age in Alzheimer's patients by modulating DNA methylation across multiple biological clocks, with significant improvements in inflammatory and metabolic biomarkers.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.